Effects of ertugliflozin monotherapy or combination therapy on glycaemic control, body weight, and blood pressure in patients with type 2 diabetes: a pooled analysis

被引：0
|
作者：
Lauring, B. [1 ]
Liu, J. [1 ]
Tarasenko, L. [2 ]
Terra, S. G. [3 ]
Huyck, S. [1 ]
Wu, L. [1 ]
Pong, A. [1 ]
Calle, R. A. [4 ]
Gallo, S. [5 ]
Darekar, A. [6 ]
Mancuso, J. P. [7 ]
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] Pfizer Inc, New York, NY USA
[3] Pfizer Inc, Andover, MA USA
[4] Pfizer Inc, Cambridge, MA USA
[5] Pfizer Pharma GmbH, Berlin, Germany
[6] Pfizer Ltd, Walton Oaks, England
[7] Pfizer Inc, Groton, CT 06340 USA
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
628
引用
收藏
页码：S305 / S305
页数：1
相关论文
共 50 条
  • [31] Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
    Bosi, E.
    Dotta, F.
    Jia, Y.
    Goodman, M.
    DIABETES OBESITY & METABOLISM, 2009, 11 (05): : 506 - 515
  • [32] Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
    Jadzinsky, M.
    Pfuetzner, A.
    Paz-Pacheco, E.
    Xu, Z.
    Allen, E.
    Chen, R.
    DIABETES OBESITY & METABOLISM, 2009, 11 (06): : 611 - 622
  • [33] Initial combination therapy with saxagliptin and metformin improves glycaemic control compared with either monotherapy alone in drug-naive patients with type 2 diabetes
    Chen, R.
    Pfuetzner, A.
    Jadzinsky, M.
    Paz-Pacheco, E.
    Xu, Z.
    Allen, E.
    DIABETOLOGIA, 2008, 51 : S38 - S38
  • [34] Glycaemic, Blood Pressure and Lipid Control in Type 1 Diabetes
    Javid, Shahzad
    O'Sullivan, Eoin P.
    Dinneen, Sean
    O'Brien, Timothy
    Dunne, Fidelma
    DIABETES, 2009, 58 : A258 - A258
  • [35] Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
    Silvina Gallo
    Roberto A. Calle
    Steven G. Terra
    Annpey Pong
    Lisa Tarasenko
    Annaswamy Raji
    Diabetes Therapy, 2020, 11 : 1849 - 1860
  • [36] Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
    Gallo, Silvina
    Calle, Roberto A.
    Terra, Steven G.
    Pong, Annpey
    Tarasenko, Lisa
    Raji, Annaswamy
    DIABETES THERAPY, 2020, 11 (08) : 1849 - 1860
  • [37] Therapeutic inertia for glycaemic and blood pressure control in patients with type 2 diabetes mellitus and the cardiovascular consequences
    Paul, S.
    Shaw, J.
    Klein, K.
    DIABETOLOGIA, 2015, 58 : S63 - S63
  • [38] Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes
    Sharma, Anukriti
    Mariam, Arshiya
    Zacherle, Emily
    Milinovich, Alex
    Bauman, Janine
    Sugano, David S.
    Noone, Josh
    Rajpura, Jigar R.
    Zimmerman, Robert S.
    Burguera, Bartolome
    Kattan, Michael W.
    Misra-Hebert, Anita D.
    Pantalone, Kevin M.
    Rotroff, Daniel M.
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5347 - 5357
  • [39] Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control
    Rosenstock, J.
    Rood, J.
    Cobitz, A.
    Huang, C.
    Garber, A.
    DIABETES OBESITY & METABOLISM, 2006, 8 (06): : 643 - 649
  • [40] Luseogliflozin, a SGLT2 inhibitor, improves glycaemic control and reduces body weight as monotherapy up to 52 weeks in Japanese patients with type 2 diabetes mellitus
    Seino, Y.
    Sasaki, T.
    Fukatsu, A.
    Ubukata, M.
    Sasaki, T.
    Kasai, Y.
    Sakai, S.
    Samukawa, Y.
    DIABETOLOGIA, 2013, 56 : S384 - S384
12345